Evaluation of combination long-acting β-2 agonists and inhaled glucocorticosteroids for treatment of asthma

Bibliography

• Global Strategy for Asthma Management and Prevention Updated 2007
   Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, et al. “Morbidity and Mortality Weekly Report,” Surveillance for Asthma. In: CDC, editor, 2002;51(SS01):1-13
   Google Scholar
• “The Costs of Asthma,” Asthma and Allergy Foundation 1992 and 1998 Study, 2000 Update
   Google Scholar
• Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2005;(4):33-40,CD003135
   Google Scholar
• Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005;(4):CD005535
   PubMedGoogle Scholar
• Fluticasone propionate and salmeterol xinafoate. Package Insert. Research Triangle Park, NC: GlaxoSmithKline 2008
   Google Scholar
• Lindmark B. Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma. Ther Adv Respir Dis 2008;2(5):279-99
   PubMedGoogle Scholar
• Budesonide and formoterol fumarate dihydrate (Symbicort). Package Insert. Dunkerque, France: AstraZeneca LP; 2009
   Google Scholar
• Palmqvist M, Arvidsson P, Beckman O, et al. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001;14(1):29-34
   PubMed Web of Science ®Google Scholar
• Michael E. Burton LMS, Schentag JJ, Evans WE. Applied pharmacokinetics & pharmacodynamics: principles of therapeutic drug monitoring 4 edition: Lippincott Williams & Wilkins, 2005
   Google Scholar
• Lotvall J. Pharmacological similarities and differences between beta2-agonists. Respir Med 2001;95(Suppl B):S7-11
   PubMed Web of Science ®Google Scholar
• Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998;102(4 Pt 2):S36-51
   PubMed Web of Science ®Google Scholar
• Rojas RA, Paluga I, Goldfrad CH, et al. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate. J Asthma 2007;44(6):437-41
   PubMed Web of Science ®Google Scholar
• Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105(6 Pt 1):1108-16
   PubMed Web of Science ®Google Scholar
• Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000;161(2 Pt 1):527-34
   PubMed Web of Science ®Google Scholar
• Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999;93(12):876-84
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Peden D, Condemi JJ, et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 2004;41(8):797-806
   PubMed Web of Science ®Google Scholar
• Nathan RA, Rooklin A, Schoaf L, et al. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clin Ther 2006;28(1):73-85
   PubMed Web of Science ®Google Scholar
• Maspero J, Guerra F, Cuevas F, et al. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: a prospective, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2008;30(8):1492-504
   PubMed Web of Science ®Google Scholar
• de Blic J, Ogorodova L, Klink R, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol 2009
   PubMedGoogle Scholar
• Noonan M, Rosenwasser LJ, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs 2006;66(17):2235-54
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003;22(5):787-94
   PubMed Web of Science ®Google Scholar
• Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 1993;52(26):2145-60
   PubMed Web of Science ®Google Scholar
• Faulds D, Hollingshead LM, Goa KL. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991;42(1):115-37
   PubMed Web of Science ®Google Scholar
• Cheung D, van Klink HC, Aalbers R. Improved lung function and symptom control with formoterol on demand in asthma. Eur Respir J 2006;27(3):504-10
   PubMed Web of Science ®Google Scholar
• van der Woude HJ, Boorsma M, Bergqvist PB, et al. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004;17(2):89-95
   PubMed Web of Science ®Google Scholar
• Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 2003;97(9):1067-74
   PubMed Web of Science ®Google Scholar
• Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000;94(6):607-11
   PubMed Web of Science ®Google Scholar
• Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129(2):246-56
   PubMed Web of Science ®Google Scholar
• Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003;123(5):1480-7
   PubMed Web of Science ®Google Scholar
• Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004;20(9):1403-18
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26
   PubMed Web of Science ®Google Scholar
• Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. statistical briefing package for joint meeting of the pulmonary-allergy drugs advisory committee, drug safety and risk management advisory committee and pediatric advisory committee on december 10–11, 2008. In: Administration USFaD, editor, 2008
   Google Scholar
• Nelson HS, Carr W, Nathan R, Portnoy JM. Update on the safety of long-acting beta-agonists in combination with inhaled corticosteroids for the treatment of asthma. Ann Allergy Asthma Immunol 2009;102(1):11-5
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006;173(5):519-26
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006;118(4):809-16
   PubMed Web of Science ®Google Scholar
• Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61(5):725-36
   PubMed Web of Science ®Google Scholar
• Busse WW, Shah SR, Somerville L, et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J Allergy Clin Immunol 2008;121(6):1407-14, 14 e1-6
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007;370(9605):2118-25
   PubMed Web of Science ®Google Scholar
• Bailey W, Castro M, Matz J, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin 2008;24(6):1669-82
   PubMed Web of Science ®Google Scholar
• Partridge MR, Hill SR. Enhancing care for people with asthma: the role of communication, education, training and self-management. 1998 World Asthma Meeting Education and Delivery of Care Working Group. Eur Respir J 2000;16(2):333-48
   PubMed Web of Science ®Google Scholar
• Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004;59(2):94-9
   PubMed Web of Science ®Google Scholar
• Lasserson TJ, Cates CJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;(3):CD004106
   PubMedGoogle Scholar